U.S., Europe, and Asia Pacific Molecular Diagnostics Market: Market Analysis on the Future Growth Prospects and Market Trends Adopted by the Competitors, Regions with Forecast by 2028 | Abbott Laboratories, Hologic, Inc., Grifols, S.A

Molecular diagnostics is increasingly becoming an integral part of patient care. Cancer-specific mutation analysis and gene expression profiling can accurately identify hereditary cancer syndromes and identify the best treatments for patients with these types of cancer. It has also helped determine the biological parameters of malignant diseases, which can be used in personalized cancer therapy. In addition, targeted treatment is becoming a common part of cancer therapy. Patients with mutations in EGFR and BRAF genes receive targeted therapy through the use of EGFR inhibitors. Tumors shed DNA, RNA, proteins, and tumor markers.

Key players operating in the market are focusing on receiving product approvals from regulatory authorities and this is expected to drive the market growth over the forecast period.

Get Research Sample PDF with Market Development Insights @ https://www.coherentmarketinsights.com/insight/request-sample/4919

For instance, in January 2019, Qiagen, a worldwide provider of molecular sample and assay technologies, launched its QIAscreen HPV PCR Test, for detection of 15 recognized high risk genotypes of human papillomavirus which is a CE-marked in vitro molecular diagnostic test.

U.S., Europe, and Asia Pacific Molecular Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 260 million cases and 5.2 million deaths due to coronavirus (COVID-19) were reported up till December 03, 2021, across the globe.

The COVID-19 pandemic and lockdown in various countries across the globe has negatively impacted the financial status of businesses across all sectors. Likewise, COVID-19 pandemic is expected to have a negative impact on the U.S., Europe, and Asia Pacific molecular diagnostics market. However, the COVID-19 pandemic has increased the demand for PPE kits and gloves, which has led to increase in production of PPE kits, thereby, assisting the market growth.

As per stated in Medical Laboratory Observer, there is increase in lab testing demands due to the emergence of the SARS-CoV-2 Virus, even to keep pace with noticed cases of COVID-19. When it was asked at surveys to the respondents regarding the increased demand of testing, some of the respondents specified that their facilities have grown up to 25%.

Buy Now to Avail Discount @ https://www.coherentmarketinsights.com/promo/buynow/4919

The most common molecular tests are based on viral RNA. These tests are known as nucleic acid amplification tests, and start with a sample of the infected person’s nose or mouth. The viral RNA is too small to be detected in tiny amounts, so signal amplification is required. This method may take a day or two to complete. This technology has the potential to revolutionize the diagnostics of many diseases.

Key players operating in the market are focusing on adoption of inorganic growth strategies such as mergers, launches, collaborations, and acquisitions, in order to strengthen their position in the global market. For instance, in February 2020, Qiagen, a worldwide provider of molecular sample and assay technologies, announced launching and CE marking of therascreen PIK3CA RGQ PCR Kit in the Europe as an aid in recognizing breast cancer patients with PIK3CA mutation.

Key Takeaways of the U.S., Europe, and Asia Pacific Molecular Diagnostics Market

• The U.S., Europe, and Asia Pacific molecular diagnostics market is expected to exhibit a CAGR of 10.7% over the forecast period, owing to rising launches, agreement and regulatory approvals of products. For instance, in September 2019, Amoy Diagnostics Co. Ltd., a pharmaceutical company engaged in research, development, production and sales of molecular diagnostic products, announced that AmoyDx Lung Cancer PCR panel was introduced as first line for patients who will potentially benefit from targeted therapy in the Lung Cancer Genomic Screening Project for Individualized Medicine (LC-SCRUM) in Japan.
• Among technology, PCR-based segment is expected to account for largest market share during the forecast period. The PCR-based segment is estimated to be valued at US$ 7,147 Mn in 2021, and is expected to register a CAGR of 10.7% and reach US$ 11,000 Mn by 2028.
• Major players operating in the U.S., Europe, and Asia Pacific molecular diagnostics market include Abbott Laboratories, Hologic, Inc., Grifols, S.A., Qiagen N.V., F.Hoffmann-La Roche Ltd., Siemens Healthineers, Becton, Dickinson and Company, Beckmann Coulter, Inc., Bio-Rad Laboratories, and Thermo Fisher Scientific Inc.